Zydus Cadila gets USFDA nod to Rivastigmine transdermal system, Rosuvastatin

Rivastigmine transdermal system and Rosuvastatin will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad, Zydus Cadila said.

New Delhi: Drug firm Zydus Cadila on March 5 said it has received nod from the US health regulator to market its Rivastigmine transdermal system, used for treatment of dementia associated with Alzheimer's and Parkinson's disease.

Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning.

The company has received approval from the United States Food and Drug Administration (USFDA) to market its Rivastigmine transdermal system 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, Zydus Cadila said in a statement.